Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Pexels / Pixabay

Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis

  A news release from Benzinga shares that biotechnology company Emerald Health Pharmaceuticals is beginning a Phase 2 clinical study on EHP-101 as a treatment for patients with systemic sclerosis.…

Continue Reading Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension
source: pixabay.com

Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension

According to a story from Pulmonary Hypertension News, the results of a recent phase 3 clinical trial have determined that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) stand…

Continue Reading Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension
ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
source: pixabay.com

Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

According to a story from Pulmonary Hypertension News, a recent study has determined that cardiopulmonary exercise testing can be an effective method to help identify systemic sclerosis patients that are…

Continue Reading Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
source: pixabay.com

Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status

According to a publication from Scleroderma News, the American Food and Drug Administration (FDA) recently granted Breakthrough Therapy status to Ofev (generic name nintedanib), as a treatment for progressive fibrosing…

Continue Reading Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
PhotoLizM / Pixabay

Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins

According to a recent press release from XBiotech, a Texas-based biotechnology company, patient dosing is now underway in a phase 1 clinical study of the Company's investigational systemic sclerosis treatment, bermekimab.…

Continue Reading Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
Findings From a Mouse Study Could Have Major Implications for Scleroderma
jarleeknes / Pixabay

Findings From a Mouse Study Could Have Major Implications for Scleroderma

According to a story from Scleroderma News, the results of a recent mouse study could have significant implications for the future of scleroderma treatment. In the study, scientists used a…

Continue Reading Findings From a Mouse Study Could Have Major Implications for Scleroderma
Study to Investigate the Development of Lung Disease in Connective Tissue Disorders
felixioncool / Pixabay

Study to Investigate the Development of Lung Disease in Connective Tissue Disorders

A study record from clinicaltrials.gov is investigating the appearance of lung problems in patients with disorders affecting connective tissue. While prior research has documented the appearance of interstitial lung disease…

Continue Reading Study to Investigate the Development of Lung Disease in Connective Tissue Disorders
Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
TeroVesalainen / Pixabay

Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease

According to a story from finanzen.at, the drug nintedanib (marketed as Ofev) has officially been approved by the US Food and Drug Administration (FDA) as a treatment for interstitial lung…

Continue Reading Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
stevepb / Pixabay

First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug

According to a story from Financial Buzz, the drug developer Emerald Health Pharmaceuticals, Inc., recently announced that the company had completed a phase 1 clinical trial for its experimental drug…

Continue Reading First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia
jarmoluk / Pixabay

New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia

According to a publication from Scleroderma News, a recent study published in Rheumatology International suggests that the majority of systemic sclerosis patients experience sarcopenia as a result of their condition. Perhaps…

Continue Reading New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia
This Form of Rare Interstitial Lung Disease is Bad News for Scleroderma Patients
kalhh / Pixabay

This Form of Rare Interstitial Lung Disease is Bad News for Scleroderma Patients

According to a story from Scleroderma News, a recent study has recommended that scleroderma patients with a rare, poorly understood form of interstitial lung disease (ILD) should receive regular monitoring…

Continue Reading This Form of Rare Interstitial Lung Disease is Bad News for Scleroderma Patients
The Drug Abatacept Appears Beneficial in Systemic Sclerosis Despite Missing Primary Endpoint
mwooten / Pixabay

The Drug Abatacept Appears Beneficial in Systemic Sclerosis Despite Missing Primary Endpoint

According to a story from Medpage Today, a recent study testing the medication abatacept (marketed as Orencia) as a treatment for diffuse cutaneous systemic sclerosis concluded with rather mixed results.…

Continue Reading The Drug Abatacept Appears Beneficial in Systemic Sclerosis Despite Missing Primary Endpoint
Study Findings Suggest Concentration of Immune Cells Could Help Predict Systemic Sclerosis
sabinurce / Pixabay

Study Findings Suggest Concentration of Immune Cells Could Help Predict Systemic Sclerosis

According to a publication from Scleroderma News, a recent study suggests that blood concentrations of certain immune cells could correlate with the severity of cases of systemic sclerosis. About Systemic…

Continue Reading Study Findings Suggest Concentration of Immune Cells Could Help Predict Systemic Sclerosis
Researchers Continue Search for Role of Type-1 Interferon Pathway in Rheumatic Disease
mohamed_hassan / Pixabay

Researchers Continue Search for Role of Type-1 Interferon Pathway in Rheumatic Disease

According to a publication from the Rheumatologist, past studies have suggested that type 1 interferons may play a significant role in determining susceptibility to several classic connective tissue diseases. Although…

Continue Reading Researchers Continue Search for Role of Type-1 Interferon Pathway in Rheumatic Disease

FDA Advisory Committee Recommends Approval of Drug to Treat Interstitial Lung Disease Caused by Systemic Sclerosis

According to a story from Healio, the US Food and Drug Administration's (FDA) Arthritis Advisory Committee recently voted 10-7 in favor of recommending the drug nintedanib as a treatment for…

Continue Reading FDA Advisory Committee Recommends Approval of Drug to Treat Interstitial Lung Disease Caused by Systemic Sclerosis
Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters
https://pixabay.com/en/sunset-sun-sisters-girl-shadow-929179/

Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters

An article from Comic Sands recently covered the story of a UK mother, Alison Beesley, who is now committed to taking care of her daughters Eliza and Eleanor full time. Eliza is nine years old and…

Continue Reading Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters

“Stampede Scleroderma” Event for Systemic Sclerosis held at the Detroit Zoo Raised Over 130,000 Dollars for Research

Systemic Sclerosis Systemic Sclerosis (Systemic Scleroderma) is a rare disease which results in the hardening of the connective tissues in the body as well as the skin. It can affect…

Continue Reading “Stampede Scleroderma” Event for Systemic Sclerosis held at the Detroit Zoo Raised Over 130,000 Dollars for Research